Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

出版年份 2018 全文链接

标题

作者

关键词

出版物

LANCET

Volume 391, Issue 10126, Pages 1163-1173

出版商

Elsevier BV

发表日期

2018-03-23

DOI

10.1016/s0140-6736(18)30207-1

向作者/读者发起求助以获取更多资源

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

LANCET

向作者/读者发起求助以获取更多资源

Protocol

Reagent

Reprint

Find the ideal target journal for your manuscript

Create your own webinar